The median state economic cost attributable to diabetes is $5.9 billion, researchers estimated, although the actual cost ranges from $694 million to $55.5 billion depending on the state. The analysis was published in the December 2018 issue of Diabetes Care.
“Our comprehensive state-specific estimates provide essential information needed by state policymakers to monitor the economic burden of the disease and to better plan and evaluate interventions for preventing type 2 diabetes and managing diabetes in their states,” researchers wrote.
Per person with diabetes, the median state cost is an estimated $18,248, according to the study. Depending on the specific state, however, it ranges from $15,418 to $30,915 per patient.
The analysis included a breakdown of costs into direct medical and indirect costs, such as lost productivity and premature mortality. Per state, median direct medical costs were estimated at $2.8 billion (ranging from $0.3 billion to $22.9 billion), or a median $8544 (ranging from $6591 to $12,953) per person with diabetes.
Indirect costs were estimated at a median $3 billion (ranging from $0.4 billion to $32.6 billion) per state. Per patient with diabetes, estimated indirect costs were a median $9672 (ranging from $7133 to $17,962).
“Economic costs attributable to diabetes were large,” researchers wrote, “and varied widely across states.”
Shrestha SS, Honeycutt AA, Yang W, et al. Economic costs attributable to diabetes in each U.S. state. Diabetes Care. 2018;41(12):2526-2534.
For articles by First Report Managed Care, click here
To view the First Report Managed Care print issue, click here